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Vaccines against Japanese encephalitis (JE) have been available for decades. Currently, most JE-endemic countries have vaccination
programs for their at-risk populations. Even so, JE remains the leading recognized cause of viral encephalitis in Asia. In 2018, the U.S.
Centers for Disease Control and Prevention and PATH co-convened a group of independent experts to review JE prevention and
control successes, identify remaining scientific and operational issues that need to be addressed, discuss opportunities to further
strengthen JE vaccination programs, and identify strategies and solutions to ensure sustainability of JE control during the next
decade. This paper summarizes the key discussion points and recommendations to sustain and expand JE control.
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INTRODUCTION
Despite the availability of safe and effective vaccines against
Japanese encephalitis (JE) for several decades (Table 1), JE virus
(JEV) remains the leading recognized cause of viral encephalitis in
Asia1. JEV is transmitted by mosquitoes and is sustained in an
enzootic cycle with pigs and wading birds as amplifying hosts.
Human cases typically occur in children and in rural areas where
people live and work in proximity to elements in the transmission
cycle, such as near rice fields or domestic pigs. There is a risk of
JEV transmission in 24 countries in Asia and the Western Pacific,
either nationally or in endemic areas2. While some regions have
nearly eliminated JE through comprehensive immunization
programs, the incidence in other areas remains high3.
While most human JEV infections are asymptomatic, severe
disease occurs in about 1 per 250 JEV infections1. JEV infection can
rapidly progress to encephalitis, with an estimated case fatality
rate of 20–30%4,5. Common symptoms include sudden onset of
high fever, chills, headache, myalgias, mental confusion, and
convulsions in pediatric patients6. Among survivors, about
30–50% have long-term neurologic sequelae with intellectual or
physical disabilities7,8. Although there is no specific treatment for
JE, supportive care improves outcome. JE burden estimates suffer
from poor surveillance resulting from the difficulty of diagnosing
JE without cerebrospinal fluid (CSF) samples and because cases
generally occur in rural areas where surveillance and laboratory
capacity might be limited.
The World Health Organization (WHO) has long recommended
JE vaccination programs in areas where JE is a public health
problem9. However, poor recognition of the burden of disease,
prioritization of other vaccines and public health interventions
over JE vaccination, and the high cost and multiple-dose regimen
of the older, inactivated mouse brain-derived vaccine limited JE
vaccine introduction. Since 2003, PATH and multiple stakeholder
organizations have worked to expand the use of WHO-
prequalified JE vaccines primarily through the support of Gavi,
the Vaccine Alliance10. Substantial impact on JE-associated deaths
and disability has been shown in countries administering JE
vaccine in childhood vaccination schedules. For example, large
vaccination campaigns targeting variable age ranges were
implemented in 31 districts in Nepal from 2006 through 2011.
JE incidence after the campaigns was 78% lower than the pre-
campaign incidence, resulting in over 3000 JE cases estimated to
have been prevented through 201411,12.
In 2018, the U.S. Centers for Disease Control and Prevention and
PATH co-convened a group of independent experts to review JE
prevention and control successes, identify remaining scientific and
operational issues that need to be addressed, discuss opportu-
nities to further strengthen JE vaccination programs, and identify
strategies and solutions to ensure sustainability of JE control
during the next decade. This paper summarizes the key discussion
points and recommendations to sustain and expand JE control
(Box 1).
ACHIEVEMENTS IN JE VACCINE DEVELOPMENT,
PREQUALIFICATION, AND POLICY ADVANCEMENT
The first inactivated mouse brain-derived vaccines were devel-
oped in the 1930s. Vaccine manufacturers in several Asian
countries developed these vaccines primarily for domestic use.
Studies of early JE vaccines have shown that human illnesses can
be eliminated with high vaccination coverage even though JEV
continues to circulate in the enzootic cycle. For example, in Japan,
universal vaccination with inactivated mouse brain-derived
vaccine virtually eliminated JE in the early 1990s12.
In the 1980s, virologists in China developed SA 14-14-2 (CD-
JEV), a live attenuated JE vaccine grown on primary hamster
kidney cells. This vaccine was introduced province by province
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and markedly reduced JE incidence in China13. Recognizing the
potential impact with greater use of CD-JEV, in 2003, PATH
partnered with the Chengdu Institute of Biological Products
(CDIBP) to export CD-JEV internationally. CDIBP and PATH
developed a new manufacturing facility compliant with good
manufacturing practices (GMP) and greater production capacity,
which opened in 2012. As part of this partnership, CDIBP also
made CD-JEV available to low- and lower middle-income countries
at a low public sector price to facilitate countries’ abilities to fund
JE vaccine introduction.
Defining an immune correlate of protection (i.e., neutralizing
antibody titer ≥1:10) in 2005 was a critical step in JE vaccine
development14. In a landmark vaccine efficacy study of mouse
brain-derived JE vaccine conducted in Thailand, more than 65,000
children were vaccinated15. Due to the high cost of clinical trials,
any subsequent efficacy trial would be expensive and likely
infeasible due to the need to vaccinate and clinically follow so
many children. However, defining an immune correlate of
protection allowed manufacturers to develop new JE vaccines
for commercial use without large and logistically challenging
vaccine efficacy trials. Several Asian and European manufacturers
developed inactivated Vero cell culture-based JE vaccines that had
a superior safety profile and were easier to manufacture than
mouse brain vaccine, but, like earlier inactivated vaccines, still
required multiple doses and periodic boosting to maintain
immunity. Another manufacturer developed a recombinant
chimeric vaccine (JE-CV) by inserting the E and prM genes of SA
14-14-2 JEV into a yellow fever 17D vaccine backbone1. Thus, in a
few decades, the JE vaccine portfolio expanded to multiple
products using a variety of vaccine technologies.
WHO prequalification is a process to validate a product’s quality,
safety, and efficacy, and to ensure a manufacturer is compliant































































































































































































































































































































































































































































































































































































































































Box 1. Key recommendations for optimal JE control beyond
2020
Reliable JE Vaccine Supply
● Optimize and ensure a reliable global supply of affordable JE vaccines
Global Coordination and Policy Optimization
● Establish and support an international coalition of partners with responsi-
bility for global coordination of JE control
● Maintain dedicated opportunities for information exchange and discussion
of emerging issues across country JE programs
● Support advocacy efforts to ensure momentum for JE control is not lost
JE Surveillance, Vaccine Utilization, and Diagnostics
● Provide technical support to countries for JE surveillance and vaccine
monitoring (e.g., coverage surveys, immunization registries)
● Support country efforts for surveillance and vaccine introduction, and
quality assurance for laboratory testing
● Monitor JEV geographic spread as land use and climate change might affect
mosquito distribution
Other Country Programmatic Support
● Troubleshoot vaccine supply issues
● When possible, integrate surveillance and vaccination programs into other
programs for efficiency and sustainability
● Conduct community advocacy and communication for maximal vaccine
acceptance
● Provide guidance for the adverse event following immunization investiga-
tions of special interest for JE
Research Priorities
● Monitor duration of protection following a single dose of live JE vaccines
● Assess vaccine safety in pregnant and immunocompromised persons
vaccinated with live JE vaccines
● Standardize and validate plaque reduction neutralization test reagents and
procedures
● Ensure reliable supply of JE diagnostic kits
● Facilitate the development of JE treatments
● Estimate JE vaccine impact globally to highlight the success of JE vaccine
programs and the need to sustain progress made
● Study safety and immunogenicity of JE vaccine co-administration with any
new vaccines that might be co-administered with JE vaccine
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needed for vaccines procured through UNICEF, procured using
Gavi support, or intended for use in WHO and other United
Nations programs. Biological E. Ltd’s JEEV, a Vero cell culture-
based vaccine, was prequalified in 2013, but initially was indicated
for adults only. Later in 2013, CD-JEV became the first JE vaccine
prequalified for children and the first Chinese vaccine to be WHO
prequalified, an accomplishment that may help additional
Chinese-manufactured vaccines enter the global markets.
After WHO prequalification of these JE vaccines, Gavi com-
mitted to financing catch-up vaccination campaigns followed by
routine vaccination within the childhood vaccination schedule,
allowing Gavi-eligible countries to introduce JE vaccine. New
vaccine introductions and expansions of JE vaccination programs
were also enabled by the WHO recommendation that JE vaccine
be introduced in all areas where JE is a public health priority,
improved JE awareness at country and community level,
government commitment, and financial and/or technical support
by organizations such as WHO, PATH, Gavi, and the Bill and
Melinda Gates Foundation3. Guidance and training materials were
developed to support country decision-making and vaccine
introduction as well as JE surveillance and measurement of
vaccine impact17–19. With products available and funding
mechanisms in place, accelerated JE control became one of eight
immunization goals in the Regional Framework for Implementa-
tion of the Global Vaccine Action Plan in the Western Pacific,
highlighting JE as a regional priority and defining operational
targets for accelerated control of JE to be achieved by 203020. As
of June 2020, 15 countries have national or subnational public
health vaccination programs in JE-endemic areas. These include
Australia (Outer Torres Strait Islands), Malaysia (Sarawak), Japan,
Republic of Korea, Thailand, Cambodia, Lao PDR, Myanmar,
Indonesia (Bali), Philippines (three high-incidence regions), China,
India (about 40–50% of districts), Nepal, Sri Lanka, and Vietnam
(Fig. 1).
STATUS OF JE SURVEILLANCE AND CONTROL
JEV is a positive-stranded, enveloped RNA flavivirus. Because of
low virus titers in infected humans and the neurotropism of JEV,
the virus is rarely isolated from human cases. Therefore the gold
standard for JE diagnosis is the presence of JE immunoglobulin M
(IgM) antibody in the CSF1. However, as a disease that occurs
predominantly in rural areas, the capacity for CSF collection,
especially in children, is often limited and lumbar punctures are
not always performed, especially in settings where treatment for
encephalitis is limited or not available.
Access to diagnostics is important because JE cannot be
clinically differentiated from other viral causes of acute central
nervous system infection such as enterovirus 7121. Important
progress in improving JE surveillance and defining disease burden
came with the development of a range of JE diagnostic kits22–25.
While three commercial JE IgM ELISA assays were previously
available in JE-endemic countries, only the InBios JE DetectTM IgM
antibody capture ELISA is still being manufactured. CSF can be
tested with the InBios JE assay alone, but, because of cross
reactivity, serum samples must also be tested with a dengue IgM
assay and results interpreted according to a CDC-devised
algorithm26.
Even when diagnostics are available, interpreting serum IgM
results in areas with co-circulation of other flaviviruses can be
complicated because antibodies against other flaviviruses often
cross react with JEV. In addition, it is well-recognized that IgM
following JEV infection can be detectable for months or years, so
there is sometimes uncertainty when JE IgM is detected in serum
whether it truly reflects JEV as the cause of a patient’s presentation
or could be persisting IgM following a previous asymptomatic
infection or mild febrile illness unrecognized as JE. A recent
analysis of IgM following vaccination with CD-JEV in a clinical trial
suggests serum IgM is common at 28 days following vaccination
but rare at 6 months following vaccination (~40% vs. 3% of
vaccinees with positive or equivocal test results by ELISA,
respectively)27. While this finding suggests that serum IgM is
unlikely to be related to vaccination administered at least six
months prior, it does not negate the importance of CSF collection
for proper JE diagnosis.
To improve and standardize JE diagnosis in JE-endemic
countries, PATH worked with partners to establish WHO JE
Laboratory Networks in WHO’s South-East Asia and Western
Pacific Regions during 2006–2008. These networks have substan-
tially increased the frequency and quality of JE laboratory testing
and continue to provide support to countries for confirmatory
testing, quality assurance, and other JE testing issues28.
Despite progress with JE diagnostics and laboratory testing,
because of the difficulty diagnosing JE, reported JE case counts
are generally considered to be underestimates of true JE
incidence. A 2011 estimate of global JE burden, in which high-
quality surveillance data from limited areas in Asia were
extrapolated to other endemic regions, calculated that 67,900 JE
cases occurred annually, of which 75% occurred in children <15
years of age29. Based on the reported case fatality rate of 20–30%
and long-term neurological sequelae among 30–50% of survivors,
it was estimated that JE caused 13,600–20,400 fatalities each year
and long-term neuropsychological sequelae in 14,300–27,200
people. In contrast to the estimate of case numbers, only 4402 JE
cases were reported through the WHO-UNICEF Joint Reporting
Form on Immunization in 2018, suggesting substantial under-
reporting2. In a vaccine impact assessment conducted in Nepal
using JE and acute encephalitis syndrome (AES) surveillance data,
AES incidence was 59% lower than expected had no JE
vaccination campaign occurred, with the absolute reduction in
AES cases substantially greater than the reduction in confirmed JE
cases, suggesting many AES cases were undiagnosed JE cases and
again highlighting the unrecognized burden of JE11.
In addition to having better burden of disease estimates, JE
surveillance is critical to inform vaccine introduction, monitor
vaccination programs and identify alternative causes of encepha-
litis, evaluate vaccine effectiveness in different epidemiological
settings, and monitor JEV expansion into new areas. WHO first
published JE surveillance standards in 2008, and they were
updated in 201830,31. Still, there continues to be substantial
variability in approach, quality, and extent of surveillance in JE-
endemic countries, based on local capacity and resources and the
need for integration into pre-existing systems2.
JE has been considered a disease of children in JE-endemic
countries; immunity to JE by natural infection is widespread by
adulthood and generally believed to be lifelong, at least in the
context of natural boosting in endemic areas32. While vaccination
has contributed to a relative shift in cases to older age groups in
some countries, other countries without vaccination programs
have also shown a substantial proportion of cases in adults, raising
the question of the need for adult vaccination32,33. JE vaccination
programs in Nepal that targeted all age groups showed the rate of
AES in individuals ≥15 years after vaccination was 77% lower than
expected, suggesting an unrecognized burden of JE in this age
group. While strong pediatric vaccination programs are the
foundation of a JE vaccination program, some countries, based
on the burden of disease and prioritization, may consider
vaccinating adults as well.
Mosquito-borne transmission is of greatest concern, although
transplacental transmission and transmission through blood
transfusion have been documented34,35. As a mosquito-borne
disease, JE incidence is highly variable based on temperature,
elevation, and rainfall. JEV is transmitted primarily by the mosquito
Culex tritaeniorhynchus. There have been limited reports of JEV
outside of Asia. In Italy, one pool of Culex pipiens was found to
contain JEV as determined by RT-PCR of a small JEV RNA fragment,
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although no virus isolation was performed. In 2016, a patient with
confirmed yellow fever infection in Angola was found to be co-
infected with a JEV genotype III virus based on deep sequencing
technology36,37. Further data are needed to confirm JEV transmis-
sion outside of Asia; however, with the global presence of Culex
vectors and amplifying hosts, it is possible JEV could emerge
outside of the traditional geographic boundaries due to popula-
tion movement into nonendemic areas that results in changes in
local farming practices and animal husbandry, expanded rice
irrigation to meet population demand, and possibly global climate
change. Although less likely, the transport of infected mosquito
vectors or their infected eggs, the importation of viremic
vertebrate hosts, or changes in bird migration patterns due to
global climate change has the potential to expand the range
of JEV38,39.
STATUS OF JE VACCINES AND VACCINATION
There have been ~15 JE vaccine products commercialized in Asia,
including several manufactured for use only in the country of
manufacture1,40. JE vaccines fall into four categories: (1) live
attenuated vaccine (i.e., CD-JEV); (2) live recombinant (chimeric)
vaccine (i.e., JE-CV); (3) inactivated Vero cell-derived vaccine; and
(4) inactivated mouse brain-derived vaccine. WHO recommends
both CD-JEV and JE-CV be administered on a single-dose schedule
starting at age 8 months and 9 months, respectively, although the
JE-CV vaccine package insert recommends a pediatric booster
dose. WHO recommends administering Vero cell JE vaccines per
the package insert, which is generally 2–3 doses with a booster
dose at variable time intervals by product. CD-JEV holds the
greatest global market share with more than 300 million doses to
date administered outside of China. WHO recommends countries
move away from mouse brain vaccines given the favorable profile
of second-generation products, and no mouse brain vaccines are
WHO prequalified3.
PATH chose CDIBP’s CD-JEV to target for global use because it
could be administered as a single-dose vaccine and marketed at
an affordable price in low-income countries in Asia. Data from
China supported high vaccine effectiveness with a strong safety
profile and PATH led additional clinical trials in other Asian
countries in accordance with international standards, as did other
manufacturers using CD-JEV as a comparison vaccine41–44. Studies
using CD-JEV vaccine generally showed seroprotection (i.e.,
neutralizing antibody titer ≥1:10) in more than 90% of vaccinees
28 days after primary vaccination, although one study using WHO-
prequalified CD-JEV found lower seroprotection rates43–48. Most
case-control studies of CD-JEV vaccine demonstrated vaccine
effectiveness at around 95% up to five years post-vaccination,
although other studies have found lower point estimates49–56.
Poor ascertainment of JE cases and accurate vaccination status is a
challenge for these studies. A vaccine effectiveness study of the
WHO-prequalified CD-JEV vaccine is currently underway. Safety of
Fig. 1 Areas with risk of Japanese encephalitis (JE) transmission and JE vaccine introduction relative to the WHO JE vaccine
prequalification year (2013). While some countries have implemented national public health JE vaccine programs, others may have only
introduced in high risk areas.
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CD-JEV has been assessed both in clinical trials and through post-
licensure passive reporting of adverse events and the vaccine has
been found to have a robust safety profile57. Reports of
encephalitis post-vaccination with CD-JEV are rare and a causal
relationship with vaccination has not been established58,59. The
WHO Global Advisory Committee on Vaccine Safety reviewed data
on CD-JEV and determined it has a strong safety profile based on
available data60.
Countries use different vaccines in country-supported JE
immunization programs (implemented either nationally or region-
ally): 11 countries use CD-JEV (Cambodia, China, India, Indonesia
(Bali), Laos, Myanmar, Nepal, Philippines, South Korea, Sri Lanka,
Thailand), four use JE-CV vaccine (Australia, Malaysia, Thailand,
and China’s Taiwan province), and three use Vero cell vaccines
(Japan, South Korea, and China’s Taiwan province). Vietnam
continues to use mouse brain vaccines. Brunei and North Korea
have used JE-CV and CD-JEV, respectively, but do not have
sustained programs, and Singapore has determined routine
vaccination is not required based on surveillance data. Bangla-
desh, Bhutan, Pakistan, Papua New Guinea, Russia, and Timor
Leste do not have JE immunization programs, but have recent or
past evidence of JEV transmission61. Several countries co-
administer CD-JEV vaccine with the measles-containing vaccines,
which has been shown convincingly not to cause immune
interference46,47,62.
PROGRAMMATIC CHALLENGES AND THREATS TO JE
VACCINATION
Despite great advances in JE vaccination and control over the last
15 years, there continue to be challenges that put these gains at
risk and may impede further progress. These challenges fall into
the categories of (1) maintaining high JE vaccine coverage, (2)
maintaining a stable JE vaccine supply, and (3) maintaining
surveillance and vaccination data.
Maintaining high JE vaccine coverage
Because of the enzootic cycle of JEV involving birds and
mosquitoes, JEV elimination from the environment is impossible.
Sustained high vaccination coverage must be maintained to
prevent human cases. There is also evidence JEV is moving into
new geographic areas, including evidence of occasional urban
transmission; consequently target areas where vaccination is
needed may shift and grow63–66. Careful diagnoses and surveil-
lance are needed to monitor JE geographic spread as human
migration, land use and climate change may affect mosquito
distribution in the future. Furthermore, general vaccine hesitancy
among parents and healthcare providers is on the rise, including
in countries affected by JE67–69. In 2019, WHO named vaccine
hesitancy as one of the top 10 threats to global health70.
Confidence in vaccination programs is essential to maintain high
JE vaccine coverage.
Maintaining a stable JE vaccine supply
CDIBP’s CD-JEV is the most widely used JE vaccine and several
low- and middle-income countries rely on it. This reliance on a
single product from one site operated by a lone manufacturer
presents numerous threats to vaccine supply. Catastrophic
events, such as infection among the pathogen-free colony of
hamsters that are a source of cells for vaccine virus growth,
natural disasters (e.g., earthquakes), or human disease outbreaks
(e.g., pandemic influenza) could threaten the global vaccine
supply. A vaccine supply continuity plan to help ensure CD-JEV
global supply and availability is needed, using methods such as
off-site bulk storage and identification of alternative sources of
manufacturing materials.
There are issues of supply and demand due to the need for
manufacturers to grow virus for either live or inactivated vaccines.
Thus, countries must assess their need for vaccines many months in
advance of usage and are unable to acquire WHO-prequalified JE
vaccines in a rapid ad hoc fashion, which makes ordering vaccines
as a response to a JE outbreak unfeasible. None of the three WHO-
prequalified vaccine producers have stockpiles of finished products
with which to respond to requests during outbreaks. For example,
the time required to produce and release a batch of CD-JEV can be
up to nine months; as a result, countries must order at least nine
months in advance. Another challenge with CD-JEV is the short
shelf life of 24 months (compared to 36 months for the other two
WHO-prequalified products). This means CD-JEV must be used
expeditiously once it arrives in countries.
WHO currently recommends that CD-JEV be given as a single-
dose vaccine without need for a booster dose. India and China,
large consumers of CD-JEV, administer the vaccine as a two-dose
primary series for programmatic reasons, which has an impact on
vaccine supply. Because CDIBP has established a public sector
price for specific JE-endemic countries, CD-JEV is currently the
most viable vaccine product for many low- and lower middle-
income countries. The cost and/or multiple-dosing regimens of
other JE vaccine products have made them less desirable in
many settings. Nonetheless, diversity is needed in the global
supply of JE vaccine.
Poor surveillance and vaccination data
Other important challenges exist with respect to disease surveil-
lance and vaccine monitoring. Poor surveillance for JE disease has
made the burden difficult to quantify in many countries, hindering
decisions about vaccine introduction. When JE vaccination has
been introduced, poor surveillance has limited availability of data to
demonstrate impact and support advocacy efforts to maintain
vaccine programs. Lack of immunization registries makes determi-
nation of vaccination status difficult over the longer term;
monitoring vaccine failures and determining vaccination status in
vaccine effectiveness studies are both critical for studying the
duration of vaccine protection and the assessment of the eventual
need of a booster dose. Challenges with the laboratory component
of surveillance include suboptimal coordination between laboratory
and epidemiology staff in some countries, and general challenges
such as sample quality on arrival in laboratories, and difficulties with
sample transport internationally for testing at reference labora-
tories. The risk of an insufficient supply of commercial JE IgM kits
because of the limited market is a large threat to routine JE
diagnostics. There remains no ready alternative if the only company
currently producing a commercial IgM ELISA discontinues produc-
tion. Critically, any reduction in support to countries from the
regional JE laboratory networks could threaten the gains made in
capacity for, and quality of, JE diagnosis.
Vaccine safety concerns, especially around severe adverse
events such as encephalitis, can trigger vaccine hesitancy. This
was seen in India when a cluster of suspected encephalitis cases
were reported shortly after a JE vaccination campaign in 2014,
though on review the cases were determined to be unrelated to
vaccination71. It is important to have robust investigations of
adverse events following immunization (AEFI) without creating
unsupported concerns. Investigation of post-vaccination ence-
phalitis has not been systematic and requires good epidemiologic
and laboratory resources to investigate properly. Enhanced AEFI
surveillance following the initiation of a JE vaccine campaign is
important. Working with stakeholders to maximize communica-
tion efforts while at the same time minimizing misinformation in
the community is critical.
Decisions about vaccine introduction in resource-limited
settings frequently require prioritization of multiple public health
interventions for diseases that affect populations. Without good JE
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burden data, it has been difficult to contextualize the importance
of JE vaccination relative to other high-priority vaccines compet-
ing for government resources, such as rotavirus and human
papillomavirus vaccines. Continued advocacy is necessary for
keeping JE on the list of priority vaccines for countries to consider.
RESEARCH GAPS
Vaccine immunogenicity and need for booster doses
Much of the earlier research on CD-JEV effectiveness and
immunogenicity was done using vaccines produced in an older
CDIBP facility that did not meet good manufacturing practice
(GMP) standards. To license and prequalify CD-JEV made in the
newer, GMP-compliant facility, a non-inferiority study compared
three lots of “new facility” vaccine with one lot of vaccine from
the older facility48. Seroprotection rates 28 days after vaccination
for recipients of the new facility vaccine were 80.2–84.5%
compared to 86.3% among recipients of the vaccine made in
the older facility. Although this was not statistically different,
seroprotection rates were noted to be higher (i.e., 90.5 to 92.1%)
in earlier clinical studies of CD-JEV47,72. Because plaque reduction
neutralization tests in these studies were performed at different
times, comparing results is difficult. Still, while the findings of the
lot-to-lot consistency trial supported the use of “newer facility”
CD-JEV, continued monitoring is required on the vaccine’s
duration of protection, which potentially could have implications
for booster doses.
With reasonable immunogenicity of CD-JEV over a sustained
period of time and an absence of reported vaccine failures with
programmatic use, WHO does not recommend JE vaccine booster
doses unless future evidence warrants it40. Data on vaccine
effectiveness studies and vaccine failure monitoring are impor-
tant to inform the need for booster doses for all WHO-
prequalified JE vaccines. Studies are in progress (e.g., a case-
control study in Bali, Indonesia) that will provide longer-term
vaccine effectiveness data (e.g., up to 5 years) and inform the
duration of protection of a single dose of CD-JEV. Studies of
antibody persistence alone are insufficient as undetectable
neutralizing antibody might not indicate the absence of
protective immunity. For example, data from a trial of JE-CV
indicated that at two years post-primary vaccination some
children who did not seroconvert with a primary JE-CV dose
exhibited an anamnestic response following a receipt of a booster
dose40. Similar findings were seen in a study of the other live JE
vaccine, CD-JEV. Children who did not seroconvert initially or no
longer had seroprotective antibody four years after immunization
were given a booster dose of CD-JEV that resulted in a strong
anamnestic response73. Anamnestic responses following revacci-
nation with live JE vaccines suggest that despite undetectable
antibodies, vaccines might be protected from clinical disease.
Should booster doses of CD-JEV ultimately be recommended, this
would have additional implications for vaccine supply and
programmatic implementation. The anamnestic response has
not been studied for inactivated JE vaccines.
Furthermore, data on safety and immunogenicity following
vaccination of special populations, such as pregnant women and
immunocompromised persons, are missing for both live vaccines,
CD-JEV and JE-CV. Research priorities across vaccine platforms are
available in WHO’s position paper on JE vaccines3.
Emerging genotypes
All licensed vaccine viruses are genotype III JEV. While studies
suggest these vaccines provide good protection against multiple
genotypes, there are questions pertaining to future vaccine
effectiveness if a new JEV genotype emerges74,75. Two genotype V
JEV isolates have been identified, one from a human and one from a
mosquito, and genotype V sequences from Culex mosquitoes also
have been recently identified76. Additional evidence is required to
determine if this genotype is emerging. If so, the question has arisen
if currently available vaccines might be less effective, based on
neutralizing antibody data and the 9% amino acid difference
between genotype V and genotype III viruses. This situation should
be monitored.
Disease sequelae and treatment options
Although the expert meeting focused on JE vaccination, there are
other research gaps related to JE and treatment. While disability
following encephalitis has long been recognized, the extent of
sequelae following mild, non-neurologic JE illness is poorly
understood. Such data could provide a better understanding of
the full burden of JE morbidity and a more comprehensive
understanding of the benefits of vaccination. Better information
on the comparative severity of JE in adults and children would
also be useful. Finally, as there is no specific treatment for JE
currently available, investigation of possible JE treatments is
another important avenue for further research. Limited clinical
trials to date have not yielded any successful compounds,
although promising targets exist77. There is a potential role of
inflammation as a contributor to poor clinical outcomes from JEV
infections, thus anti-inflammatory agents in combination with
antiviral agents might be effective; this deserves further study77.
RECOMMENDATIONS TO OPTIMIZE JE CONTROL
The challenges defined above highlight that despite major
achievements in JE control, efforts are required to continue and
sustain progress. Experts at the meeting identified key recom-
mendations in the following categories: (1) vaccine supply, (2)
global coordination and policy optimization, (3) JE surveillance
and diagnostics, (4) country programmatic support, and (5)
research priorities.
Reliable JE vaccine supply
An adequate supply of JE vaccine is essential to JE control and is
currently at risk as discussed above. A reliable JE vaccine supply
requires vaccination schedules be optimized, countries improve
lead-time for ordering JE vaccine, and vaccine manufacturers
develop contingency plans for events such as natural disasters or
other disruptions of vaccine supply. JE vaccine manufacturers with
pre-qualified products currently in limited use globally are
encouraged to make their products available and affordable to
affected countries. At a minimum, country licensure of more than
one product will allow product switching if the need arises.
Global coordination and policy optimization
A coalition of key partners should be established that is
responsible for exchange of information, best practices, and
coordinated actions among JE control programs. This coalition
would serve as a technical resource for countries and should
maintain a web-based library of materials to support vaccine
introduction and monitoring. As national and international
partners have highlighted the utility of biannual WHO JE
biregional (i.e., South-East Asia and Western Pacific regions)
meetings to share experiences and lessons learned, these meet-
ings should continue under the coordination of the coalition.
Biregional meetings are important for information exchange and
discussion of new or emerging issues. Advocacy for JE vaccine
introduction is still needed to ensure that the momentum
achieved through the efforts of PATH, WHO and its regional
offices, and other partners, WHO prequalification of JE vaccines,
and Gavi support, is not lost. As additional data become available
(see Research Priorities), re-evaluation of global JE vaccine policies
(e.g., the need for booster doses) might be warranted.
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JE surveillance, vaccine utilization, and diagnostics
The need for strong surveillance and diagnostics does not end when
a vaccine is introduced in the country. Many JE-endemic countries
will still need support in the areas of JE surveillance, diagnostics, and
vaccination program monitoring after JE vaccine has been
introduced. JE surveillance support will help decision-making for
countries planning to introduce JE vaccine to understand disease
burden and target vaccination geographically and by age. In
countries with JE vaccination, JE surveillance and immunization
registries are important to help identify program deficiencies, assess
long-term vaccine protection, and monitor the geographic spread of
JE. JE vaccination program monitoring should be improved through
vaccine coverage surveys and better completion of the WHO/
UNICEF Joint Reporting Form on Immunization.
Other country programmatic support
WHO Regional offices need to be supported as they directly assist
countries with these issues—surveillance and vaccine introduc-
tion, quality assurance for laboratory testing, and troubleshooting
vaccine supply issues. To maximize efficiencies across programs
and ensure stable funding, efforts in surveillance, diagnostics, and
vaccine coverage monitoring should be combined for JE and
other vaccine-preventable diseases; this will also help integrate JE
into routine immunization activities. Community advocacy and
communication must be supported for maximal vaccine accep-
tance, especially during vaccination campaigns. To help address
vaccine safety concerns and vaccine hesitancy, all reported serious
AEFIs should be investigated promptly and properly, but with the
care that the investigations do not create inappropriate concern
that they are caused by vaccination if other etiologies are more
likely. Readily available resources to guide AEFI investigations,
particularly of encephalitis post-vaccination, would be helpful.
High-priority research needs
● The potential need for a JE vaccine booster dose to achieve
life-long protection against JE. Longer-term vaccine effective-
ness studies and documentation of vaccine failures through
careful JE surveillance will be the most convincing data to
indicate if booster doses are required for CD-JEV or JE-CV and
the frequency of boosting for inactivated JE vaccines.
● Vaccine safety in special populations. To address research
gaps on vaccine safety in immunocompromised persons and
pregnant women who are knowingly or unknowingly
vaccinated with CD-JEV and JE-CV, vaccine registries for these
populations are needed.
● Laboratory and diagnostic issues. Additional diagnostic tests
are urgently needed. Market shaping for JE ELISA kits will likely
be needed through Gavi and other agencies, as other
manufacturers have not shown interest in the development
of similar kits due to the limited market. The use of new
technologies and platforms for diagnostics could hold
promise in the future but would require investments.
Standardized and validated plaque reduction neutralization
test reagents and procedures may allow comparison of
immunogenicity results across laboratories.
● JE treatment. To help facilitate JE treatment research, expert
consultation is needed with the aim of identifying the next
drugs that should be tested in humans as well as to discuss
the design of therapeutic trials, including types of studies,
suitable locations, and outcomes to be measured.
● JE vaccine impact. To document the importance of JE
vaccination and the need for sustained efforts, it will be
important to conduct a retrospective impact study of the
number of JE cases, disabilities, and deaths averted and to
estimate the total cost savings from JE vaccination.
Mathematical modeling of expected JE cases in the absence
of vaccination could be a potential approach to overcome
the deficiencies in JE surveillance. Such studies could
consolidate country support for existing JE immunization
programs and place JE in proper context alongside other
vaccine-preventable diseases to support decision-making for
JE vaccine introduction.
● Safety and immunogenicity of JE vaccine co-administration
with new vaccines. Ongoing safety and immunogenicity
studies of co-administration of JE vaccines with newly
introduced vaccines (e.g., typhoid conjugate vaccine) should
be conducted when there is a programmatic desire to co-
administer vaccines.
CONCLUSIONS
JE control in Asia through immunization programs is a public
health success. Together with affected country drive to develop
new vaccines and control JE, international investments into an
Asian domestic vaccine manufacturer enabled an affordable
product and expanded access to this life-saving vaccine. However,
more work is needed to secure the gains made and accelerate
control of JE by expanding the use of JE vaccines in JE-endemic
areas that do have immunization programs or do not have
adequate programs.
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